

Press Release – Basel, Switzerland December 19<sup>th</sup> 2005

## Global Expansion of Genedata's Screening Analysis Collaboration with Roche

**Basel, Switzerland** - Genedata announces the multi-year expansion of its collaboration with Roche to include all Roche high throughput screening (HTS) facilities in North America and Europe. Scientists at Roche use Genedata Screener® to estimate the biological potency of thousands of compounds as part of a unique lead discovery workflow.

"We are pleased that Roche sees the value of our computational solutions for lead discovery", says Dr. Daniel Keesman, CEO of Genedata. Initiated originally at Roche's research facility in Basel, the collaboration has integrated Genedata's data quality evaluation and analysis workflow with Roche's global screening infrastructure.

Roche has developed a unique process for screening entire compound libraries at multiple concentrations, a requirement for accurate potency estimation. Methods for analyzing compound potency tend to be time intensive and are difficult to standardize across entire compound libraries. Genedata Screener® successfully automates and standardizes potency estimation, enabling a genuinely high throughput workflow.

"Screener has been deployed successfully at four major sites in a very short time period, assuring a return on the customer's investment", added Dr. Michael Lindemann, Business Head Genedata Screener. The system is based on an open and scalable architecture that enables tight IT integration without resource-intensive customization.

---

### Contact

Genedata AG  
Dr. Tobe Freeman  
Public Relations  
Phone +41 61 697 8510  
Fax +41 61 697 7244  
tobe.freeman@genedata.com  
www.genedata.com

**About Genedata**

Genedata specializes in computational solutions for life science research, drug discovery, and drug development. The Company combines a comprehensive, scientifically validated computational platform with expert scientific consulting services to provide tailor-made solutions for specific applications and multiple therapeutic areas. Founded in 1997 as a spin-off from Novartis, the Company is privately held and has grown to an interdisciplinary, international team of dedicated experts. Genedata is headquartered in Basel (Switzerland) with subsidiaries and branch offices in Munich (Germany), San Francisco (USA), and Boston (USA). The Company is also represented by Infocom Corporation (Japan), DigiGenomics (Taiwan), and Research Instruments (Singapore, Malaysia). For more information about Genedata, please visit: [www.genedata.com](http://www.genedata.com).

**About Roche**

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2004 sales by the Pharmaceuticals Division totalled 21.7 billion Swiss francs, while the Diagnostics Division posted sales of 7.8 billion Swiss francs. Roche employs roughly 65,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. For more information about the Roche Group, please visit [www.roche.com](http://www.roche.com).

---

**Disclaimer**

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.